(R)-Omeprazole is the inactive isomer of omeprazole , a gastric proton-pump inhibitor. A stereoselective hydroxylation of (R)-omeprazole is mediated primarily by cytochrome P450 (CYP) 2C19, whereas CYP3A4 favors sulfoxidation of the active (S)-enantiomer . (R)-Omeprazole has been shown to act as a reversible direct-acting and metabolism-dependent inhibitor of CYP2C19 in pooled human liver microsomes (IC50 = 8.1 μM).
Omeprazole acid is a medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton pump inhibitor and as such blocks the release of stomach acid.
Omeprazole N-oxide, a metabolite of the gastric proton pump inhibitor omeprazole, serves as a potential impurity in commercial omeprazole preparations.
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is an effective and orally active proton pump inhibitor that works by inhibiting the H+, K+-ATPase enzyme in the gastric parietal cells, leading to a reduction in acid secretion. It is a promising compound for investigating symptomatic gastroesophageal reflux disease [1] [2] [3].